Dozens of widely prescribed medications can damage or disrupt the jaw, and the problems they cause range from bone death and involuntary clenching to gum overgrowth and chronic pain. The most recognized culprits are bone-targeting drugs used for osteoporosis and cancer, but antidepressants, antipsychotics, blood-pressure medications, corticosteroids, and several classes of cancer therapy also belong on the list. Because many of these drugs treat serious conditions, the jaw-related risks often go unmentioned until symptoms appear.
Bisphosphonates and Denosumab
The jaw problem most closely tied to a specific drug class is medication-related osteonecrosis of the jaw, commonly abbreviated MRONJ. It occurs when jawbone tissue dies and becomes exposed through the gums, failing to heal for weeks or months. The primary offenders are bisphosphonates, a group of drugs prescribed to strengthen bones in osteoporosis and to prevent skeletal complications in cancers that spread to bone. Potent nitrogen-containing bisphosphonates such as zoledronic acid, pamidronate, alendronate, and risedronate work by blocking an enzyme inside bone-resorbing cells, which ultimately causes those cells to malfunction and die.1Annals of Oncology. Potential mechanisms of action of bisphosphonates and the development of osteonecrosis of the jaw That is the intended therapeutic effect, but the jawbone turns over faster than most other bones and depends heavily on those same cells for routine maintenance. When maintenance stalls, minor trauma from a tooth extraction or even a dental infection can set off a chain of bone death that the body cannot repair.
Denosumab, a different type of bone-targeting drug that works through the immune system rather than accumulating in bone mineral, also causes MRONJ. How its risk compares to bisphosphonates is still debated. One study of patients with osteoporosis found the rate of jaw osteonecrosis was roughly six times higher with denosumab than with bisphosphonates.2PubMed. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis A large Taiwanese study, however, found similar or slightly lower rates with denosumab during the first two years, with a meaningful difference emerging only from the third year onward.3PubMed Central. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan The practical takeaway is that both drug types carry real MRONJ risk, and switching from a bisphosphonate to denosumab does not necessarily eliminate that risk. If anything, having used a bisphosphonate before switching to denosumab could add to it.
Anti-Angiogenic and Targeted Cancer Drugs
Cancer drugs that block the growth of new blood vessels have emerged as another source of jaw osteonecrosis. Sunitinib, used for kidney cancer and certain gastrointestinal tumors, suppresses blood-vessel formation in a way that slows bone repair and damages the lining of the mouth. Both effects create conditions for MRONJ, and the risk climbs when sunitinib is combined with bisphosphonates.4PubMed Central. Osteonecrosis of the jaws produced by sunitinib: A systematic review Bevacizumab, another anti-angiogenic drug widely used in colorectal and other cancers, has similarly been linked to jawbone necrosis through the same blood-supply disruption.5PubMed. Osteonecrosis of the mandible associated with bevacizumab therapy
Because these drugs are typically given to people who are also receiving bisphosphonates or denosumab for bone metastases, it is difficult to separate each drug’s individual contribution. Clinicians increasingly treat this as a cumulative problem: the more bone-affecting and blood-vessel-suppressing medications a patient is on, the greater the overall MRONJ risk.
Antidepressants and Teeth Grinding
Selective serotonin reuptake inhibitors, the most commonly prescribed class of antidepressants, can trigger bruxism, the involuntary grinding or clenching of the teeth. The jaw muscles contract forcefully during sleep or even during the day, wearing down tooth enamel, causing jaw pain, and straining the temporomandibular joint. Bruxism is underrecognized as a drug side effect partly because patients often do not notice nighttime grinding and partly because doctors rarely ask about it.6PubMed Central. Sertraline-induced bruxism: a case report and review of the literature
Among SSRIs, fluoxetine and sertraline are the most commonly reported triggers, and venlafaxine, a closely related serotonin-norepinephrine reuptake inhibitor, also appears frequently in case reports. Symptoms tend to start within three to four weeks of beginning the medication and, encouragingly, often resolve within a similar window after the drug is stopped or adjusted.7PubMed Central. SSRI-associated bruxism: A systematic review of published case reports Buspirone, a mild anti-anxiety medication, has been used successfully as an add-on treatment. It appears to counteract the mechanism behind SSRI-induced bruxism by boosting dopamine activity in the brain, and it also helps with other movement-related side effects of these drugs.8European Psychiatry. Use of buspirone in selective serotonin reuptake inhibitor-induced sleep bruxism
The distinction between stress-related bruxism (which is extremely common) and drug-induced bruxism matters here. If you started grinding your teeth or waking with jaw soreness shortly after beginning an SSRI, that timing is a strong clue. Mention it to your prescriber, because a dose reduction, a switch to a different antidepressant, or the addition of buspirone can often solve the problem without giving up the mental-health benefit of the medication.
Antipsychotics and Jaw Dystonia
Antipsychotic medications, both older and newer generations, can cause involuntary, repetitive movements of the jaw, tongue, and face. This condition, called tardive oromandibular dystonia, involves sustained or spasming contractions of the chewing muscles. It often begins with repetitive jaw movements that impair chewing and progressively damage the teeth.9PubMed Central. Interdisciplinary recognizing and managing of drug-induced tardive oromandibular dystonia: two case reports The jaw can be forced open, clamped shut, or deviated to one side, depending on which muscles are affected.
Even newer “atypical” antipsychotics are not free of this risk. Olanzapine, for example, has been documented causing a jaw dystonia that produced an open bite and persistent jaw pain in a patient being treated for depression. In that case, withdrawing the drug resolved both the bite problem and the pain.10Oral Science International. Oromandibular dystonia induced by olanzapine and mirtazapine: A case report The tricky part is that these symptoms develop slowly, sometimes years into treatment, and dentists may not connect them to a psychiatric medication. The complaints can seem vague at first, like a bite that feels “off” or muscles that tire during meals, and by the time the dystonia is recognized, the teeth and jaw joint may already be damaged.
Corticosteroids and Jaw Bone Damage
High-dose corticosteroids, whether taken for autoimmune disease, organ transplant, or severe COVID-19, can cause avascular necrosis of bone, a condition in which bone tissue dies because its blood supply is cut off. The hip is the most commonly affected joint, but the jaw is not immune. A series of cases documented during the COVID-19 pandemic showed patients developing spontaneous avascular necrosis in the jaw after receiving high-dose steroids over a short period for severe illness.11PubMed Central. Post-COVID steroid induced avascular necrosis of the jaw: Emerging challenge in India Before the pandemic, jaw involvement was considered rare and was typically associated with long-term steroid use, sometimes combined with recent tooth extraction.
Children are also at risk. Glucocorticoids are among several drug classes prescribed to kids that have been shown to lower bone mineral density and impair bone growth, which for the jaw specifically means that long-term use during development can affect how the bones of the face grow and mineralize.12PubMed Central. Medication-Related Impacts on Pediatric Bone Health
Chemotherapy and Neuropathic Jaw Pain
Vincristine, a chemotherapy drug used to treat leukemia, lymphoma, and several other cancers, is well known for damaging nerves. What is less commonly discussed is that the nerves supplying the jaw and face are frequent targets. In a study of patients receiving vincristine, more than half developed orofacial pain as a manifestation of the drug’s nerve toxicity, with the temporomandibular joint, the lower jaw, the throat, the ears, and the lower teeth all affected.13PubMed. Jaw and other orofacial pain in patients receiving vincristine for the treatment of cancer The pain follows the distribution of the trigeminal nerve, which is the main sensory nerve for the face and jaw, and the glossopharyngeal nerve, which serves the throat and ear area.
Other vinca alkaloids in the same drug family can produce similar neuropathy, and the risk of severe nerve damage increases when these chemotherapy drugs are given alongside certain antifungal medications, particularly triazoles, which slow the body’s ability to clear the chemotherapy drug from the bloodstream.14PubMed Central. Effect of antifungal triazoles on vinca alkaloid neurotoxicity in pediatric patients: A retrospective case series analysis and literature review For patients undergoing chemotherapy, new or unexplained jaw pain should be reported promptly, because adjusting the dose or spacing of treatment may prevent more severe nerve injury.
Calcium Channel Blockers and Gum Overgrowth
Calcium channel blockers, prescribed for high blood pressure and certain heart conditions, can cause dramatic overgrowth of the gum tissue. Among this drug class, nifedipine is the most frequent offender. Gum enlargement can begin within three weeks of starting the medication and typically stabilizes at around ten weeks. Amlodipine and lercanidipine have also been reported to cause the problem.15PubMed Central. Gingival overgrowth as secondary effect of calcium channel blockers administration. A case report
The overgrowth is more likely with daily doses above 10 mg, is more common in men, and worsens in the presence of dental plaque, cavities, or poorly fitting dental work. While this is technically a gum problem rather than a bone or joint problem, severe gingival overgrowth can make chewing painful, shift the bite, and create pockets where bacteria thrive, eventually threatening the teeth and the underlying jawbone. Switching to a different blood-pressure medication or improving oral hygiene can slow or reverse the process, but in some cases surgical trimming of the gum tissue is needed.
Anticholinergic Medications and Dry Mouth
A wide range of medications with anticholinergic effects, including certain antihistamines, bladder drugs, older antidepressants, and some antipsychotics, cause dry mouth by reducing saliva production. The jaw problems from dry mouth are indirect but cumulative: reduced saliva leads to faster tooth decay, more mouth sores, difficulty chewing and swallowing, and orofacial pain.16PubMed Central. Anticholinergic medication: Related dry mouth and effects on the salivary glands Over months or years, accelerated tooth loss changes how the bite distributes force, which can strain the temporomandibular joint and the muscles that move the jaw.
Dry mouth is so common among older adults taking multiple medications that it often gets dismissed as a minor annoyance. But for the jaw, it sets up a slow cascade: less saliva means more cavities, more cavities means more extractions, more extractions means more stress on remaining teeth and the jaw itself. If you are on anticholinergic drugs and notice your mouth feeling persistently dry, talk to your dentist about protective strategies like prescription fluoride toothpaste and saliva substitutes.
Immune Checkpoint Inhibitors
Immune checkpoint inhibitors, a newer class of cancer immunotherapy, work by releasing the brakes on the immune system so it can attack tumors. A well-known side effect is that the unleashed immune system sometimes attacks the body’s own tissues. Inflammatory arthritis is the most common joint-related complication, and when it affects the temporomandibular joint, it produces pain, stiffness, and limited mouth opening. Most patients respond to low doses of corticosteroids or standard anti-inflammatory medications, and many cases resolve when the immunotherapy is stopped.17PubMed Central. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis A small number develop severe symptoms requiring stronger immune-suppressing drugs.
Local Anesthetics and Trismus
This one catches people off guard because the drug is not something you take at home. Local anesthetic injections used in dental procedures, particularly inferior alveolar nerve blocks for work on lower teeth, can occasionally cause trismus, a painful inability to open the mouth fully. The problem can stem from needle trauma to the chewing muscles, bleeding into the muscle, or infection at the injection site.18PubMed Central. Trismus Following Inferior Alveolar Nerve Block: A Case Report Trismus after a dental injection is usually temporary, but repeated or incorrectly placed injections can cause scarring in the muscle tissue that limits jaw opening for weeks or longer.
What Makes Some People More Vulnerable
Not everyone on these medications develops jaw problems, and researchers have identified several factors that amplify the risk. For MRONJ specifically, dental procedures are a major trigger. Tooth extractions, root amputations, and extractions of teeth that are already inflamed all significantly raise the odds. One multicenter study found that root amputation carried the highest risk, followed by concurrent immunosuppressive therapy and extraction of lower teeth.19PubMed. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study Longer duration of high-dose bone-modifying therapy also played a clear role.
Interestingly, one study found that tooth extraction itself did not increase MRONJ risk when the analysis controlled for other variables. Instead, leaving infected teeth in place appeared to be the bigger danger, and extracting those teeth actually lowered the risk of osteonecrosis developing.20PubMed Central. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients This challenges the older assumption that all dental extractions should be avoided in patients on bisphosphonates. The current thinking emphasizes eliminating sources of infection rather than avoiding extractions at all costs.
Diabetes, concurrent corticosteroid use, and poor oral hygiene all compound the risk further.21PubMed Central. Rodents as an animal model for studying tooth extraction-related medication-related osteonecrosis of the jaw: assessment of outcomes People taking multiple jaw-affecting drugs at once face the highest danger, and that combination is not rare in cancer treatment, where a patient might be on a bisphosphonate, an anti-angiogenic agent, and corticosteroids simultaneously.
Prevention Before You Start a Medication
The single most effective strategy for preventing drug-related jaw problems is getting your teeth in good shape before starting a high-risk medication. For MRONJ, guidelines recommend a dental evaluation, treatment of cavities, extraction of teeth that cannot be saved, and optimization of oral hygiene before beginning antiresorptive or anti-angiogenic drugs.22PubMed Central. Comprehensive Review of Prevention and Management Strategies for Medication-related Osteonecrosis of the Jaw (MRONJ) This “get ahead of it” approach is far more effective than trying to manage osteonecrosis after it develops.
For antidepressant-induced bruxism, awareness is the first line of defense. If you are starting an SSRI, pay attention to morning jaw soreness, tooth sensitivity, or headaches around the temples in the first month. Catching it early allows your prescriber to intervene before the grinding causes lasting damage to your teeth or jaw joint. In cases where bruxism persists despite medication changes, botulinum toxin injections into the masseter and temporalis muscles have shown long-term benefit. One case report documented resolution of masticatory pain and restored jaw movement lasting seven years after a single injection.23PubMed. Long-term efficacy of onabotulinum toxin in treating persistent myofascial pain and masticatory muscles hypertone in an adolescent with bruxism
When MRONJ Does Develop
If osteonecrosis of the jaw occurs despite preventive efforts, treatment depends on how advanced it is. Early-stage lesions, where the bone exposure is limited and there is no active infection, respond well to conservative management with antibiotics, antiseptic mouth rinses, and pain control. A recent study found that all stage 1 MRONJ lesions healed completely regardless of whether they were managed conservatively or surgically.24PubMed Central. Is medical therapy alone efficient for the management of Medication-related osteonecrosis of the jaw bones (MRONJ) in all stages?: a comparative single-center case-control study For moderate cases, both approaches worked similarly well.
Advanced-stage MRONJ is more complicated. Surgical removal of dead bone is sometimes necessary, but outcomes are mixed. In one study, secondary osteonecrosis occurred in about 70% of advanced lesions that were treated surgically, while medical therapy alone led to spontaneous shedding of the dead bone in a majority of cases.24PubMed Central. Is medical therapy alone efficient for the management of Medication-related osteonecrosis of the jaw bones (MRONJ) in all stages?: a comparative single-center case-control study Another study examining bone healing with imaging found that advanced lesions actually showed better healing outcomes than early ones, with improvements in bone density and reduced lesion volume, particularly when surgical treatment was used.25PubMed Central. Stage-related changes of bone density and volume in treatment of medication-related osteonecrosis of the jaw A temporary pause in the offending drug, known as a drug holiday, is also part of the treatment picture. Conservative management of early lesions appears to benefit from a longer drug holiday, while surgical cases in advanced stages showed positive healing effects on both soft and hard tissue regardless of holiday duration.25PubMed Central. Stage-related changes of bone density and volume in treatment of medication-related osteonecrosis of the jaw
Medications That Affect Children’s Jaw Growth
Growing jaws face a distinct set of drug risks. Children’s bones are still developing, and medications that lower bone mineral density or impair growth can have consequences that are not immediately visible but affect the structure of the face over time. Glucocorticoids, antiepileptic drugs, chemotherapy agents, and psychotropic medications have all been shown to impair bone development in children, leading to lower bone density and higher fracture risk.12PubMed Central. Medication-Related Impacts on Pediatric Bone Health For the jaw, this can translate to altered growth patterns, delayed eruption of permanent teeth, and a weaker foundation for dental structures. Pediatricians and dentists collaborating early on monitoring plans can help catch growth disturbances before they become permanent.